Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Featured Stories


Competitive Dealmaking Market Shifts To Smaller M&A, Partnering

Dollars spent on biopharma M&A so far in 2024 may not be as high as in 2023, but dealmakers say deal volume is robust with many factors influencing the overall value of transactions this year.

BIO Deals Financing

Sarepta Obtains Broader DMD Label For Elevidys

The gene therapy is now approved for all ambulatory boys with Duchenne muscular dystrophy ages 4 and older. The revised label also includes accelerated approval for non-ambulatory patients.

Approvals Gene Therapy Business Strategies

Better Tolerability Could Make Zealand’s Amylin Drug A Future Obesity Leader

The Danish company’s amylin analog looks like a match for GLP-1 agonists on efficacy, and better on tolerability, and is now moving quickly into Phase II.

Asia Spotlight

Sun’s Gandhi On US Specialty Journey Sans ‘Baggage’, Deuruxolitinib

Sun’s CEO (North America) Abhay Gandhi tells Scrip how not many gave the firm a chance in the US with Ilumya, now with global sales of over half a billion dollars, and outlines prospects of deuruxolitinib for alopecia areata. India’s top-ranked drug maker also has an eye on China R&D assets.


Commercial Business Strategies

More coverage from Scrip's team in Asia

Scrip Podcast

Insights and perspectives on commercial, R&D, deal-making and business strategy developments.

MORE PODCASTS

 

Scrip Originals

Pipeline Watch: 12 Approvals And 18 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Finance Watch: SPACs Attempt A Comeback Ahead Of Full IPO Recovery

Public Company Edition: Several special purpose acquisition corporations have emerged, including various health care- and life science-focused SPACs. Also, Alvotech entered into a $965m refinancing agreement and Avidity grossed $461m in a follow-on offering, among other updates.

Financing Growth

Executives On The Move: New Hires At Eisai, Connect Biopharma, Actylis And More

Recent moves in the industry include new chief executive officers at Connect Biopharma, Skyhawk Therapeutics and Actylis, plus I-Mab gets new chief medical officer.

Leadership Executive Changes

Stock Watch: Thoroughly Moderna Missteps

When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.

Stock Watch Coronavirus COVID-19
Interviews

Parexel On Reimbursement Support, Federated Data Sharing, Diversity Through Communities

Parexel’s chief strategy officer, clinical EVP and India head share thoughts on a winner’s mindset for artificial intelligence, benefits of a “federated approach” to clinical data sharing, support for reimbursement and a cascading impact of obesity treatments, in a two-part interview with Scrip.

Research & Development Business Strategies

Sun’s Gandhi On US Specialty Journey Sans ‘Baggage’, Deuruxolitinib

Sun’s CEO (North America) Abhay Gandhi tells Scrip how not many gave the firm a chance in the US with Ilumya, now with global sales of over half a billion dollars, and outlines prospects of deuruxolitinib for alopecia areata. India’s top-ranked drug maker also has an eye on China R&D assets.

Commercial Business Strategies

Finance Watch: Lilly’s Gateway Labs, Deerfield’s Cure Offer Biotechs Space To Grow

Private Company Edition: Scrip spoke with the leaders of Gateway Labs and Cure at the BIO International Convention about their mini ecosystems. Also, radiopharmaceutical firm ITM raised €188m ($201.9m), Santa Ana Bio emerged with $168m and Alzheon’s series E totaled $100m.

BIO Financing

BIO: Bayer Operational Model Benefits From Its Arm’s Length Biotechs

There is a lot of structural change going on at the German major but it is learning from the way its wholly owned subsidiaries such as AskBio and BlueRock are run.

Business Strategies Deals
See All
Graphics

New Promise, Looming Competition For DMD In China

With several new drugs progressing for the estimated 70,000 patients in China with DMD, a recent setback for Nippon Shinyaku's contender and progress for Chinese gene therapy developers are adding both uncertainty and likely competition in an untapped market with pressing medical need.

China Clinical Trials

Bukwang Adds To Stacking Mid-Stage Failures In Parkinson's

Bukwang and subsidiary Contera have become the latest to fail to progress a novel Parkinson's therapy to late-stage trials after a Phase II miss, although several other Korean firms remain in the race for the challenging indication, albeit mainly in Phase I-II.

South Korea Clinical Trials

Development Versus Dealmaking: How To Obtain A Blockbuster

Most of the companies with blockbuster drugs approved over the past decade oversaw their clinical development internally. Lilly holds the lead with eight blockbusters developed in-house.

Companies Deals

Rapid Rise Or Slow Roll: How Long Does It Take To Become A Blockbuster?

Scrip analyzed data on top-selling drugs to see how long it takes to surpass $1bn in revenues and grow into $5bn and even $10bn brands.

Launches Commercial
See All
Recent Stories

TIL The CARs Come Home: How Cell Therapy’s Solid Tumor Future Is Shaping Up

Iovance’s Amtagvi won FDA accelerated approval in February, and Adaptimmune’s afami-cel may not be far behind, but cell therapies for solid tumors come with some extra challenges.

CAR-T Cancer

Pipeline Watch: 12 Approvals And 18 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

J&J Heats Up IL-23 Inflammatory Bowel Space With Tremfya Crohn's US Filing

AbbVie's rival interleukin-23 drug Skyrizi is now approved in the US for both principal types of inflammatory bowel disease – ulcerative colitis and Crohn’s disease. Tremfya may not be too far behind.

Gastrointestinal Drug Review

Finance Watch: SPACs Attempt A Comeback Ahead Of Full IPO Recovery

Public Company Edition: Several special purpose acquisition corporations have emerged, including various health care- and life science-focused SPACs. Also, Alvotech entered into a $965m refinancing agreement and Avidity grossed $461m in a follow-on offering, among other updates.

Financing Growth

Gilead’s Twice-Annual Sunlenca Posts Zero Infection Rate In PrEP Trial

Lenacapavir is halfway to the pivotal data needed to file for twice-annual administration in PrEP, after demonstrating superiority against both background incidence of HIV infections and Truvada.

Clinical Trials Business Strategies

Anti-TROP2 ADCs Lung Cancer Futures Likely Lie In Earlier-Stage Disease

The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers. 

ASCO Clinical Trials

Jazz’s Suvecaltamide Fails In Tremor Trial, But Parkinson’s Study Continues

A Phase IIb trial evaluating suvecaltamide failed to show a statistically significant benefit versus placebo on an assessment scale for essential tremor.

Clinical Trials Neurology

Roche Adds Ascidian’s RNA-Writing To Its Neurology Push

A first big pharma partnership for Ascidian, headed up by ex-Biogen research head Michael Ehlers, as the Swiss firm expands its gene editing and neuroscience efforts.

Deals StartUps and SMEs

AbbVie Doubles Down In IBD With Skyrizi Ulcerative Colitis Approval

The US major's blockbuster is already well established as a treatment for Crohn’s disease but the latest thumbs-up from the US FDA means Skyrizi is the first interleukin-23 inhibitor approved for both principal types of inflammatory bowel disease.

Approvals Gastrointestinal

Executives On The Move: New Hires At Eisai, Connect Biopharma, Actylis And More

Recent moves in the industry include new chief executive officers at Connect Biopharma, Skyhawk Therapeutics and Actylis, plus I-Mab gets new chief medical officer.

Leadership Executive Changes

Parexel On Reimbursement Support, Federated Data Sharing, Diversity Through Communities

Parexel’s chief strategy officer, clinical EVP and India head share thoughts on a winner’s mindset for artificial intelligence, benefits of a “federated approach” to clinical data sharing, support for reimbursement and a cascading impact of obesity treatments, in a two-part interview with Scrip.

Research & Development Business Strategies

€80m Cash Boost Helps iOnctura Accelerate Eye Cancer Candidate

The proceeds from the impressive series B financing will help progress roginolisib through Phase II trials.

Cancer Financing
UsernamePublicRestriction

Register